Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Cellectar Biosciences Announced That Iopofosine I 131 In Combination With External Beam Radiation Therapy Was Safe And Tolerated In Phase 1 Trial In Recurrent Head And Neck Cancer

Author: Benzinga Newsdesk | March 04, 2024 07:42am

Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients

Durability of clinical activity achieved 67% Overall Survival and 42% Progression Free Survival at One Year

Posted In: CLRB